Comparison of short-acting intramuscular antipsychotic medication: Impact on length of stay and cost

American Journal of Therapeutics

Volumn 18, Issue 4, 2011, Pages 300-304

  Leung, Jonathan G ^a   Benedetti, Amanda M ^b   Frazee, Lawrence A ^b,c   Myers, Nancy ^c  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b AKRON GENERAL MEDICAL CENTER   (United States)

^c NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

Author keywords

aripiprazole; Haloperidol; olanzapine; short acting intramuscular antipsychotic; ziprasidone

Indexed keywords

ARIPIPRAZOLE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; ZIPRASIDONE;

ADULT; AGITATION; ARTICLE; COMPARATIVE STUDY; DEMOGRAPHY; DRUG COST; ELECTRONIC MEDICAL RECORD; FEMALE; HOSPITAL ADMISSION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; COHORT STUDIES; DRUG COSTS; FEMALE; HALOPERIDOL; HUMANS; INJECTIONS, INTRAMUSCULAR; LENGTH OF STAY; MALE; MIDDLE AGED; PIPERAZINES; PSYCHOMOTOR AGITATION; QUINOLONES; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; THIAZOLES;

EID: 79960562728     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181d48320     Document Type: Article

References (21)

1. Moosa MYH, Jeenah FY, Kazadi N. Treatment Adherence. SAJP. 2007;12:41-45.
2. Strutton DR, Gutierrez B, Blanchette CM. Influence of medication treatment patterns on resource use for patients hospitalized for schizophrenia. Am J Health Syst Pharm. 2008;65:42-48.
3. Marder SR. A review of agitation in mental illness: treatment guidelines and current therapies. J Clin Psychol. 2006;67(S10):13-21. (Pubitemid 44433622)
4. Wu EQ, Birnbaum HG, Shi L, et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry. 2005;66:1122-1129. (Pubitemid 41442278)
5. Martinez JM, Russell JM, Salinas JA, et al. Impact of early intervention with intramuscular antipsychotic medication in an acute care setting. Eur Neuropsychopharmacol. 2000;10(S3):295.
6. Altamura AC, Sassella F, Santini A, et al. Intramuscular preparations of antipsychotics. Drugs. 2003;63:493-512.
7. Wagstaff AJ, Easton J, Scott LJ. Intramuscular olanzapine. CNS Drugs. 2005;19:147-164.
8. Preskorn SH. Pharmacokinetics and therapeutics of acute intramuscular ziprasidone. Clin Pharmacokinet. 2005:44: 1117-1133. (Pubitemid 41483699)
9. Tulloch KJ, Zed PJ. Intramuscular olanzapine in the management of acute agitation. Ann Pharmacother. 2004; 38:2128-2135. (Pubitemid 40169386)
10. Breier A, Meehan K, Birkett M, et al. A double-blind, placebo-controlled dose-response comparison of intra-muscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry. 2002;59:441-448. (Pubitemid 34477680)
11. Wright P, Lindborg SR, Birkett M, et al. Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during during the first 24 hours of treatment. Can J Pyschiatry. 2003;48:716-720.
12. Brooks S, Lucey JV, Gunn KP. Ziprasidone IM study group. Intramuscular ziprasidone compared with in-tramuscular haloperidol in the treatment of acute psychosis. J Clin Psychiatry. 2000;61:933-941. (Pubitemid 32058009)
13. Andrezina R, Josiassen RC, Marcus RN, et al. Intramus-cular aripiprazole for the treatment of acute agitation in patient with schizophrenia or schizoaffective disorder. Psychopharmacology. 2006;188:281-292.
14. Tran-Johnson TK, Sack DA, Marcus RN, et al. Efficacy and safety of aripiprazole in patients with acute agitation. J Clin Psychiatry. 2007;68:111-119.
15. Citrome L. Comparison of intramuscluar ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. J Clin Psychiatry. 2007;68: 1876-1885. Geodon [Package Insert]. New York, New York: Pfizer; 2007.
16. Battaglia J, Moss S, Rush J, et al. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, pro-spective, double-blind, emergency department study. Am J Emerg Med. 1997;15:335-340. (Pubitemid 27284198)
17. Garza-Trevino ES, Hollister LE, Overall JE, et al. Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. Am J Psychiatry. 1989;146:1598-1601. (Pubitemid 20014731)
18. Yildiz A, Sachs GS, Turgay A. Pharmacological manage-ment of agitation n emergency settings. Emerg Med J. 2003;20:339-346. (Pubitemid 36873910)
19. Battaglia A. Pharmacological management of acute agitation. Drugs. 2005:65:1207-1222.
20. Naso AR. Optimizing patient safety by combined use of intramuscular olanzapine and parenteral benzodiazaines. Am J Health Syst Pharm. 2008;65:1180-1183. (Pubitemid 351874863)
21. Zyprexa [Package Insert]. Indianapolis, IN: Eli Lilly and Company; 2006.